Under construction – not a live service
Sign in
Taking people in HungaryPhase 2

Tests PF-07328948 pill in adults with heart failure

Tests a new study pill against a placebo in adults with heart failure.

Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Key facts

Where
Budapest, Budapest X, Budapest XII, Budapest XIII, Hatvan, Pecs, Sopron, and Székesfehérvár, HungarySee the 8 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to under 80 who have had heart failure for at least 3 months and still have symptoms.

Age
18 years to under 80 years (up to 79 years)
Sex
All sexes can join.
Disease stage
Heart failure diagnosed at least 3 months ago, with New York Heart Association Class II-IV symptoms and left ventricular ejection fraction greater than 40%. Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score below 85 and six-minute walking distance greater than 75 meters.
Earlier treatment
People with known hypersensitivity to an SGLT2 inhibitor, or a contraindication to one, cannot join.

Main reasons for not taking part

  • Type 1 diabetes mellitus or liver cirrhosis
  • Any condition that can affect how the medicine is absorbed into the body
  • Major surgery planned during the study that affects walking ability, in the study doctor's opinion
  • History of heart transplantation, or currently listed for a heart transplant
  • Planned use of IV vasodilators and/or inotropes

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Source: NCT06991257, who can take part

Where in Hungary

  • Budapesti Jahn Ferenc Del-pesti Korhaz es RendelointezetBudapest, HungaryTaking people
  • Ezustfeny Klinika Kft.Budapest X, HungaryTaking people
  • Semmelweis UniversityBudapest XII, HungaryTaking people
  • Central Hospital Of Northern Pest Military HospitalBudapest XIII, HungaryTaking people
  • BKS Research KftHatvan, HungaryTaking people
  • Da Vinci Spa Kft.Pecs, HungaryTaking people
  • New Medical Center Kft.Sopron, HungaryTaking people
  • Complex Rendelo Med Zrt.Székesfehérvár, HungaryTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Pfizer
Trial code
NCT06991257EU 2024-518438-94-00
Record updated
23 October 2026
Original description
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).Read full original descriptionShow less

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Inclusion: aged 18 years to < 80 years; clinically confirmed to have a diagnosis of heart failure for at least 3 months; New York Heart Association Class II-IV symptoms; left ventricular ejection fraction greater than 40%; Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score < 85; Six-minute walking distance greater than 75 meters.

Exclusion: Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor; Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor; Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body; History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes.

This study is seeking participants who are:.

ClinicalTrials.gov NCT06991257 · EU CTIS 2024-518438-94-00